PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model
about
Insights into the key roles of proteoglycans in breast cancer biology and translational medicineHeparan sulfate signaling in cancerMechanisms of heparanase inhibitors in cancer therapy.Elemene inhibits the migration and invasion of 4T1 murine breast cancer cells via heparanase.MYCN-dependent expression of sulfatase-2 regulates neuroblastoma cell survival.PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samplesThe heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabineHeparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activationThe potential of heparanase as a therapeutic target in cancerHeparan sulfate and heparanase as modulators of breast cancer progressionHeparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.Loss of HSulf-1: The Missing Link between Autophagy and Lipid Droplets in Ovarian Cancer.The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.Heparan sulfate inhibitors and their therapeutic implications in inflammatory illnesses.The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues.Involvement of heparanase in the pathogenesis of acute kidney injury: nephroprotective effect of PG545.Heparanase: From basic research to therapeutic applications in cancer and inflammation.Prognostic significance of heparanase expression in primary and metastatic breast carcinoma.Prophylactic anti-heparanase activity by PG545 is anti-viral in vitro and protects against Ross River virus disease in mice.A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.Establishment of a murine breast tumor model by subcutaneous or orthotopic implantation.Gubenyiliu II Inhibits Breast Tumor Growth and Metastasis Associated with Decreased Heparanase Expression and Phosphorylation of ERK and AKT Pathways.Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.
P2860
Q28085548-222F9C96-337E-4511-AD9B-5A11D9A007F1Q28657828-612F6CB8-E053-4920-A373-F1F1DCF658E2Q30244089-A0C1EA20-B528-4DFC-BE40-8392307779F7Q33828297-CC375063-3286-4B8E-8387-CECD252489D8Q34438510-4F7BE0C8-AFAD-4CD2-BC92-38DC3357A0ABQ35470322-1D8B2A06-FC47-48C8-9E48-372C036EFF89Q35741596-0F8CE83E-F1A2-4030-BC2A-27FA131F42ABQ36430711-AF26FD41-E65F-479F-86A5-5F27AE7CF5A3Q36452903-77C00FA6-0238-41BE-987E-110C83DE20F6Q37105315-322CFA64-7721-4815-8CB2-BE36E7C9EBE3Q37499263-68D2054F-3DE5-4AC0-8401-72D863937EDAQ37627650-73DE0005-33FE-441E-BFE8-79ADC545BBA0Q38078480-6B24D668-17CB-4CA7-BCB6-AE9A52B1AC17Q38116039-7DC09AC1-2BBA-4346-BAED-061C634A367DQ38238094-8F80C70B-B10C-42F1-9F80-EA0579177155Q41817665-1675F617-7EF6-4FC4-9679-513AE153DA8FQ41855773-FEEB2801-F217-49C1-882E-DA35640FC313Q42587945-D1A451FB-FE3F-4B1A-9BA3-1589B08BE52BQ49787551-EA56F82F-C165-4A31-BAAA-21624E085224Q50044331-B5AFF8C1-34EA-4C93-8E75-F2C58BB5047FQ52659459-DA2C0BF1-B06B-4D77-A504-EB2521D1B4ACQ53418683-78AD1B7B-D49B-4D03-AC06-F4A89713A4F0Q53495018-FE528CA0-66F5-4DCA-AA70-B6DB19293513Q55414494-2D2C3FE9-539F-4C72-B735-86E90C1E9422
P2860
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
PG545, a heparan sulfate mimet ...... the 4T1 breast carcinoma model
@ast
PG545, a heparan sulfate mimet ...... the 4T1 breast carcinoma model
@en
PG545, a heparan sulfate mimet ...... the 4T1 breast carcinoma model
@nl
type
label
PG545, a heparan sulfate mimet ...... the 4T1 breast carcinoma model
@ast
PG545, a heparan sulfate mimet ...... the 4T1 breast carcinoma model
@en
PG545, a heparan sulfate mimet ...... the 4T1 breast carcinoma model
@nl
prefLabel
PG545, a heparan sulfate mimet ...... the 4T1 breast carcinoma model
@ast
PG545, a heparan sulfate mimet ...... the 4T1 breast carcinoma model
@en
PG545, a heparan sulfate mimet ...... the 4T1 breast carcinoma model
@nl
P2093
P2860
P1433
P1476
PG545, a heparan sulfate mimet ...... the 4T1 breast carcinoma model
@en
P2093
Edward Hammond
Keith Dredge
Ralf Brandt
P2860
P304
P356
10.1371/JOURNAL.PONE.0052175
P407
P577
2012-01-01T00:00:00Z